Conditions: Type 2 Diabetes Mellitus
Keywords: Phase 2 type 2 diabetes mellitus PF-04937319
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 345
Healthy volunteers: no

Brief summary:
B1621007 is designed to study the safety and efficacy of PF-04937319 in patients with type 2 diabetes

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None arm 4: None arm 5: None arm 6: None

Interventions: intervention 1: Placebo intervention 2: PF-04937319 - 3mg intervention 3: PF-04937319 - 20mg intervention 4: PF-04937319 - 50mg intervention 5: PF-04937319 - 100mg intervention 6: Sitagliptin - 100mg
Intervention descriptions: intervention 1: double-dummy placebo tablets administered once-daily for 84-days intervention 2: PF-04937319 3mg administered as tablets once-daily for 84-days intervention 3: PF-04937319 20mg administered as tablets once-daily for 84-days intervention 4: PF-04937319 50mg administered as tablets once-daily for 84-days intervention 5: PF-04937319 100mg administered as tablets once-daily for 84-days intervention 6: Sitagliptin 100mg administered as tablets once-daily for 84-days

Protocol document: